Fig. 10: Summary of the overall findings.

PRRX1 is the master transcription factor (mTF) that determines the lineage of highly pro-tumorigenic cancer-associated fibroblasts (CAFs) with a myofibroblastic phenotype through remodeling a super-enhancer landscape. Targeting the mTF, PRRX1 belonging to the CAF subgroup with a myofibroblastic phenotype may be a promising cancer treatment strategy.